November 3, 2015
GlaxoSmithKline: Two drug injectable regimen for HIV therapy study shows positive result
ViiV Healthcare, a global specialist HIV company with GSK (GlaxoSmithKline), Pfizer Inc. and Shionogi Limited as shareholders, announced on Tuesday that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks.